# Alzheimer’s Breakthroughs: Tau Targets & Treatment Setbacks

Newsy: Alzheimer’s News Weekly
Published: 2026-08-31T13:30:00.434Z
Source: https://newsyai.com/edition/569574d9-502f-4f93-aff9-f64fabb16310
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

**Alzheimer’s Treatment Briefing: Tau Targeting and Mixed Signals from New Studies**

**Coverage period: August 24–August 31, 2026**

Broad searches across news outlets, research databases, regulatory announcements, and trial registries turned up several developments this week. The most relevant updates for treatment include new details on a tau-targeting drug, fresh biomarker support for an oral candidate, and a major setback for a popular diabetes/weight-loss drug class in Alzheimer’s. Here are the key stories worth highlighting, ranked by potential impact on care.

**1. Diranersen Phase 2 results show mixed but promising signals for slowing Alzheimer’s decline**  
**Overview**  
Biogen released topline results from its Phase 2 CELIA trial of diranersen, an investigational drug given by injection into the spinal fluid that aims to lower tau protein production. The study of 416 people with early Alzheimer’s did not meet its main goal of showing a clear dose-response relationship on a key thinking-and-functioning score. However, across doses, it suggested slowing of cognitive decline—most notably at the lowest dose tested (60 mg every 24 weeks), with about 26% slowing on one main measure and similar benefits on others. Tau levels dropped substantially in the brain and spinal fluid. The company plans to move forward to larger Phase 3 testing.[[1]](https://www.neurologylive.com/view/topline-phase-2-celia-results-show-diranersen-misses-primary-end-point-early-ad)

**Why this matters**  
Tau is like the tangled wiring inside brain cells that disrupts signals and leads to cell damage. While approved drugs mainly target amyloid plaques (the sticky buildup outside cells), this approach tackles tau directly. Even partial slowing at an early stage could buy meaningful time—think of it as applying brakes to a car that’s starting to roll downhill, potentially extending independence. The lower-dose benefit and plan for Phase 3 keep momentum going for combination strategies that hit both amyloid and tau.

**2. New biomarker data strengthen case for valiltramiprosate (ALZ-801) in early-stage disease**  
**Overview**  
Fresh analyses from earlier trials of valiltramiprosate, an oral pill that targets toxic amyloid clumps, showed it lowered a key blood marker of tau (p-tau217) by about 36% in people with mild cognitive impairment, while placebo groups saw rises. These changes lined up with better scores on thinking tests and protection of brain volume in the hippocampus (a memory center). The drug showed these effects especially in the mildest stage, with no excess brain swelling risks seen in some other treatments. Alzheon plans another Phase 3 study.[[2]](https://www.neurologylive.com/view/biomarker-data-across-studies-support-disease-targeted-effects-valiltramiprosate)

**Why this matters**  
An easy-to-take pill that affects both amyloid and downstream tau changes could complement infusions or work for people who can’t or prefer not to receive them. Picture it as a daily shield that not only reduces one type of debris but also helps protect the brain’s “control center” for memory. Strong links between biomarker drops and real-world thinking/brain benefits add confidence that the drug is hitting the right targets early, when the brain still has reserves.

**3. Large trials of semaglutide (a GLP-1 drug) miss goal of slowing Alzheimer’s progression**  
**Overview**  
Novo Nordisk’s two big Phase 3 studies (Evoke and Evoke+) of semaglutide—an injectable diabetes and weight-loss medication—in more than 3,800 people with early Alzheimer’s found no significant benefit over placebo on the main measure of cognitive and functional decline after two years. Some Alzheimer’s-related biomarkers improved, but the drug did not slow symptom progression. The company is discontinuing extension periods and will share more details later.[[3]](https://www.biopharmadive.com/news/novo-glp1-alzheimers-trials-evoke/806256/)

**Why this matters**  
GLP-1 drugs have shown strong benefits for heart health and metabolism, raising hopes they might also protect the brain through reduced inflammation or better energy use. This clear negative result on the primary goal tempers those expectations for Alzheimer’s specifically. It highlights that not every promising mechanism will translate—much like how a tool that works well in one workshop setting may not fit another. Researchers may still explore combinations or different dosing, but it underscores the need for diverse approaches beyond single pathways.

**What this means for care right now**  
- Approved treatments like lecanemab (Leqembi) and donanemab (Kisunla) remain options for eligible early-stage patients with confirmed amyloid; the new at-home lecanemab autoinjector is now available in the U.S. for starting therapy.  
- Lifestyle factors (heart health, exercise, sleep, social engagement) and clinical trial participation continue to be important supports.  
- Talk with your doctor about the latest diagnostic tools (blood tests, imaging) if cognitive changes are a concern—earlier clarity helps guide decisions.  
- Watch for more data from upcoming conferences.

**Sources**  
- NeurologyLive coverage of diranersen CELIA topline results (August 31, 2026).  
- NeurologyLive biomarker analyses for valiltramiprosate (August 31, 2026).  
- BioPharma Dive on semaglutide trial results (August 25, 2026).  
- Comprehensive web searches for Alzheimer’s news, trials, and announcements covering August 24–31, 2026 (conducted August 31, 2026).  

New data on tau and oral options continue to broaden the toolkit, while large negative trials remind us that progress often comes in steps.
